Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of “Hold” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned a consensus recommendation of “Hold” from the nineteen brokerages that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $146.00.

ILMN has been the subject of a number of research reports. Royal Bank Of Canada initiated coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Evercore reissued an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Guggenheim raised their price objective on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Finally, JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th.

Illumina Stock Performance

Shares of Illumina stock opened at $176.55 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a 52 week low of $88.00 and a 52 week high of $182.84. The stock has a 50 day moving average price of $149.62 and a two-hundred day moving average price of $137.73. The stock has a market capitalization of $26.71 billion, a PE ratio of 32.10, a price-to-earnings-growth ratio of 3.30 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm posted $0.97 earnings per share. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts anticipate that Illumina will post 5.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO Scott D. Ericksen sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at $463,146,860.76. This represents a 7.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Illumina by 7.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after purchasing an additional 79 shares in the last quarter. HighPoint Advisor Group LLC lifted its holdings in shares of Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after purchasing an additional 80 shares in the last quarter. Meeder Advisory Services Inc. lifted its holdings in shares of Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares in the last quarter. Toronto Dominion Bank lifted its holdings in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its holdings in shares of Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 96 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.